Northwest Biotherapeutics, Inc.
NWBO
$0.23
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.72% | -20.71% | -33.83% | 9.60% | 14.57% |
| Total Depreciation and Amortization | 5.54% | 10.95% | 17.95% | 15.94% | 22.37% |
| Total Amortization of Deferred Charges | 4.85% | -6.76% | 4.38% | -25.58% | -14.78% |
| Total Other Non-Cash Items | 50.37% | 15.71% | 43.10% | -60.11% | -63.80% |
| Change in Net Operating Assets | 2,334.94% | 3,719.89% | 370.72% | -38.83% | -117.56% |
| Cash from Operations | 25.15% | 1.41% | -6.30% | -18.16% | -24.63% |
| Capital Expenditure | 59.69% | 62.95% | 70.50% | 73.86% | 67.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 59.69% | 62.95% | 70.50% | 73.86% | 67.82% |
| Total Debt Issued | -24.62% | 12.71% | 2.61% | 28.88% | 109.98% |
| Total Debt Repaid | -363.62% | -618.31% | -272.21% | -296.76% | -4.67% |
| Issuance of Common Stock | 424.98% | 604.35% | 817.41% | 328.67% | 45.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -98.38% | -68.58% | -38.48% | -34.15% | -29.68% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -100.00% | -98.95% | -85.24% | -78.70% |
| Cash from Financing | -14.84% | 7.98% | 7.63% | 11.20% | 24.36% |
| Foreign Exchange rate Adjustments | -386.82% | -205.29% | 347.61% | -41.17% | 272.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.51% | 108.11% | 101.01% | 5.11% | 142.76% |